Skip to main content
Clinical Trials/NCT04852393
NCT04852393
Completed
N/A

A Prospective Evaluation of the Safety and Clinical Effects of Ultrasound-guided Cervical Medial Branch Blocks

Montreal General Hospital1 site in 1 country500 target enrollmentMay 5, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Neck Pain
Sponsor
Montreal General Hospital
Enrollment
500
Locations
1
Primary Endpoint
Delayed complications
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

In this study we will prospectively examine the safety and clinical effects of ultrasound-guided cervical medial branch blocks.

Detailed Description

While several clinical trials have found that ultrasound guidance provides similar accuracy to fluoroscopy and reduces performance times for cervical medial branch blocks, larger studies documenting safety-related outcomes are lacking. In addition, although cervical medial branch blocks are an accepted tool to diagnose neck pain originating from the cervical facets, there are reports of long-lasting analgesic effects in a subset of patients, suggesting that these blocks may have long-term benefits. We therefore propose to prospectively examine the incidence of adverse events, as well as the clinical long-term effects of ultrasound-guided cervical medial branch blocks, in a cohort of pain clinic patients undergoing these procedures as part of their usual care.

Registry
clinicaltrials.gov
Start Date
May 5, 2021
End Date
October 1, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Roderick Finlayson

Professor

University of British Columbia

Eligibility Criteria

Inclusion Criteria

  • Consenting patients over 18 years of age undergoing cervical medial branch blocks as part of their usual care and who have a pain intensity of at least 5/10 (at rest or on movement) and a pain duration of at least 4 months.

Exclusion Criteria

  • Inability to communicate or complete follow up questionnaires
  • Known bleeding disorder or coagulopathy
  • Patients on antiplatelet medication other than aspirin and those on anticoagulants (coumadin, AT III agents)
  • Inability to visualize targeted structures on ultrasound
  • Presence of acute radiculopathy of new onset neurological symptoms in the upper extremities
  • Patients with bilateral neck pain if only one side is treated

Outcomes

Primary Outcomes

Delayed complications

Time Frame: 14 days after block

Proportion of patients with delayed block-related complications including any of the following: redness/irritation/swelling at injection site, hematoma, infection, skin bruising, soreness at injection site or increased pain, any neurological symptoms (new onset radicular pain, numbness/weakness or paresthesia in upper extremities).

Immediate complications

Time Frame: Immediately after block

Proportion of patients with immediate block-related complications including any of the following: vasovagal, local anesthetic toxicity (dizziness, tinnitus, altered LOC, seizure) and trauma to non-targeted neural structures (paresthesia or other neuro symptoms)

Secondary Outcomes

  • PHQ-9(Pre-block then at 1,2 and 3 months post block.)
  • GAD-7(Pre-block then at 1,2 and 3 months post block.)
  • PCS(Pre-block then at 1,2 and 3 months post block.)
  • Patient reported pain(Pre-block, then every 2 weeks for 3 months.)
  • NDI(Pre-block, then every 2 weeks for 3 months.)
  • PGIC(Pre-block, then every 2 weeks for 3 months.)

Study Sites (1)

Loading locations...

Similar Trials